Aduhelm reignites ques­tions around ties be­tween phar­ma and pa­tient ad­vo­ca­cy orgs

In the lat­est round of pa­tient ad­vo­ca­cy and the FDA, the drug re­view­er ap­proved Bio­gen and Ei­sai’s Alzheimer’s dis­ease med Aduhelm over the ad­vice of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.